PMID- 32736706
OWN - NLM
STAT- MEDLINE
DCOM- 20210212
LR  - 20210212
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 529
IP  - 3
DP  - 2020 Aug 27
TI  - Central blockage of nesfatin-1 has anxiolytic effects but does not prevent 
      corticotropin-releasing factor-induced anxiety in male rats.
PG  - 773-777
LID - S0006-291X(20)31100-1 [pii]
LID - 10.1016/j.bbrc.2020.05.163 [doi]
AB  - Nesfatin-1, a pleotropic peptide, was recently implicated in the regulation of 
      anxiety and depression-like behavior in rats. However, the underlying mechanisms 
      remain unclear so far. Thus, this study aimed to investigate the role of 
      endogenous nesfatin-1 in the mediation of anxiety and depression-like behavior 
      induced by corticotropin-releasing factor (CRF). Therefore, normal weight male 
      intracerebroventricularly (icv) cannulated Sprague Dawley rats received two 
      consecutive icv injections of anti-nesfatin-1 antibody or IgG control antibody 
      followed by CRF or saline, before being exposed to a behavioral test. In the 
      elevated zero maze test, assessing anxiety and explorative behavior, blockade of 
      nesfatin-1 using an anti-nesfatin-1 antibody under basal conditions increased the 
      number of entries into the open arms compared to control antibody/vehicle 
      (1.6-fold, p < 0.05) and the time in open arms compared to the other groups 
      (p < 0.05). Control antibody/CRF-treated animals tended to spend less time in the 
      open arms compared to control antibody/vehicle (0.7-fold, p = 0.17), an effect 
      not altered by the nesfatin-1 antibody (control antibody/CRF-treated animals vs. 
      nesfatin-1 antibody/CRF group, p = 1.00). In the novelty-induced hypophagia test, 
      assessing anhedonia as part of depression-like behavior, no significant 
      differences were observed between the four groups for the latency to the first 
      bout, number of bouts and the amount of palatable snack eaten (p > 0.05). In 
      summary, CRF tended to increase anxiety and explorative behavior an effect not 
      altered by blockade of nesfatin-1, whereas no significant effect of CRF on 
      anhedonia was observed. Blockade of endogenous nesfatin-1 significantly decreased 
      anxiety-like behavior giving rise to a physiological role of brain nesfatin-1 in 
      the mediation of anxiety.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Schalla, M A
AU  - Schalla MA
AD  - Charite Center for Internal Medicine and Dermatology, Department for 
      Psychosomatic Medicine, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of 
      Health, 12203, Berlin, Germany.
FAU - Kuhne, S G
AU  - Kuhne SG
AD  - Charite Center for Internal Medicine and Dermatology, Department for 
      Psychosomatic Medicine, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of 
      Health, 12203, Berlin, Germany.
FAU - Friedrich, T
AU  - Friedrich T
AD  - Charite Center for Internal Medicine and Dermatology, Department for 
      Psychosomatic Medicine, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of 
      Health, 12203, Berlin, Germany.
FAU - Kobelt, P
AU  - Kobelt P
AD  - Charite Center for Internal Medicine and Dermatology, Department for 
      Psychosomatic Medicine, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of 
      Health, 12203, Berlin, Germany.
FAU - Goebel-Stengel, M
AU  - Goebel-Stengel M
AD  - Charite Center for Internal Medicine and Dermatology, Department for 
      Psychosomatic Medicine, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of 
      Health, 12203, Berlin, Germany; Department of Internal Medicine, Helios Clinic, 
      Rottweil, Germany; Department of Psychosomatic Medicine and Psychotherapy, 
      University Hospital Tubingen, Germany.
FAU - Long, M
AU  - Long M
AD  - Exzellenzcluster NeuroCure, Charite University Medicine, Berlin and Institute of 
      Biology, Humboldt University, Berlin, Germany.
FAU - Rivalan, M
AU  - Rivalan M
AD  - Exzellenzcluster NeuroCure, Charite University Medicine, Berlin and Institute of 
      Biology, Humboldt University, Berlin, Germany.
FAU - Winter, Y
AU  - Winter Y
AD  - Exzellenzcluster NeuroCure, Charite University Medicine, Berlin and Institute of 
      Biology, Humboldt University, Berlin, Germany.
FAU - Mori, M
AU  - Mori M
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, Maebashi, Japan.
FAU - Rose, M
AU  - Rose M
AD  - Charite Center for Internal Medicine and Dermatology, Department for 
      Psychosomatic Medicine, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of 
      Health, 12203, Berlin, Germany; Department of Quantitative Health Sciences, 
      Medical School University of Massachusetts, Worcester, MA, USA.
FAU - Stengel, A
AU  - Stengel A
AD  - Charite Center for Internal Medicine and Dermatology, Department for 
      Psychosomatic Medicine, Charite-Universitatsmedizin Berlin, Corporate Member of 
      Freie Universitat Berlin, Humboldt-Universitat zu Berlin, and Berlin Institute of 
      Health, 12203, Berlin, Germany; Department of Psychosomatic Medicine and 
      Psychotherapy, University Hospital Tubingen, Germany. Electronic address: 
      andreas.stengel@med.uni-tuebingen.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200719
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Anti-Anxiety Agents)
RN  - 0 (Antibodies)
RN  - 0 (Nucb2 protein, rat)
RN  - 0 (Nucleobindins)
RN  - 9015-71-8 (Corticotropin-Releasing Hormone)
SB  - IM
MH  - Animals
MH  - Anti-Anxiety Agents/*therapeutic use
MH  - Antibodies/*therapeutic use
MH  - Anxiety/*chemically induced/*drug therapy/prevention & control
MH  - *Corticotropin-Releasing Hormone
MH  - Depression/chemically induced/drug therapy/prevention & control
MH  - Male
MH  - Nucleobindins/*antagonists & inhibitors
MH  - Rats, Sprague-Dawley
OTO - NOTNLM
OT  - Behavior
OT  - CRF
OT  - Depression
OT  - Gut-brain axis
OT  - NUCB2
COIS- Declaration of competing interest A.S. is consultant for a & r Berlin, 
      Boehringer-Ingelheim, Takeda and Dr. Wilmar Schwabe. No conflicts of interest 
      exist.
EDAT- 2020/08/02 06:00
MHDA- 2021/02/13 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/05/05 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/08/02 06:00 [entrez]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/02/13 06:00 [medline]
AID - S0006-291X(20)31100-1 [pii]
AID - 10.1016/j.bbrc.2020.05.163 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2020 Aug 27;529(3):773-777. doi: 
      10.1016/j.bbrc.2020.05.163. Epub 2020 Jul 19.